MOBILion Systems Inc. has raised $15.4 million in Series A financing. The round was led by Agilent Technologies, with participation from IP Group Inc., Hostplus, Cultivation Capital, and iSelect Fund.

MOBILion, a life science company developing an advanced analytical instrument platform that identifies the most challenging molecules to accelerate biologic drug development and improve diagnostic insights, intends to use the funds to support the development of its patented ion mobility separations technology, called Structures for Lossless Ion Manipulation. This technology delivers high-resolution, high-throughput analysis to the pharmaceutical industry to enhance the characterization of biologic therapeutics and accelerate biomarker discovery.

MOBILion is commercializing SLIM technology-based products that are integrated with several mass spectrometry platforms to advance the capabilities of current liquid chromatography-mass spectrometry analytical workflows and efficiently reveal previously undetectable molecules.

In addition to expanding the team and advancing product development, MOBILion plans to advance its drug and diagnostic programs with biopharma and academic collaborators as well as generate fee-for-service revenue through their new applications development laboratory.